Which therapy has a promoting effect on spleen and bone marrow?

Granulocyte-Colony Stimulating Factor (G-CSF) is a key hematopoietic growth factor that primarily acts to stimulate the production and release of neutrophils from the bone marrow. This factor is particularly crucial in situations where the body needs to increase its white blood cell count, such as during chemotherapy or in certain bone marrow disorders.

G-CSF promotes the proliferation and differentiation of progenitor cells in the bone marrow, leading to a boost in the production of neutrophils. Additionally, G-CSF has effects on the spleen, where it can enhance the mobilization of hematopoietic stem cells and promote the recovery of the immune system during or after stress.

While options such as Erythropoietin and Filgrastim also relate to bone marrow function, they have more specific roles. Erythropoietin primarily stimulates the production of red blood cells, focusing less on the overall myeloid lineage and not having a significant promoting effect on the spleen. Filgrastim is a form of G-CSF, thus sharing a similar mechanism; however, G-CSF is the broader category encompassing this function. Interleukin-2 plays a different role in the immune response,